ERBB2 and gastric cancer: By contrast, HER2-targeted ADCs explored in the second-line setting showed promising results; in January 2021, based on the robust data from DESTINY-Gastric01 phase II trial, the U.S. FDA approved T-Dxd ADC for patients with metastatic GC who have received a prior trastuzumab-based regimen (58).